These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36928316)

  • 1. A new generation M
    Huang C; Shuai H; Qiao J; Hou Y; Zeng R; Xia A; Xie L; Fang Z; Li Y; Yoon C; Huang Q; Hu B; You J; Quan B; Zhao X; Guo N; Zhang S; Ma R; Zhang J; Wang Y; Yang R; Zhang S; Nan J; Xu H; Wang F; Lei J; Chu H; Yang S
    Signal Transduct Target Ther; 2023 Mar; 8(1):128. PubMed ID: 36928316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olgotrelvir, a dual inhibitor of SARS-CoV-2 M
    Mao L; Shaabani N; Zhang X; Jin C; Xu W; Argent C; Kushnareva Y; Powers C; Stegman K; Liu J; Xie H; Xu C; Bao Y; Xu L; Zhang Y; Yang H; Qian S; Hu Y; Shao J; Zhang C; Li T; Li Y; Liu N; Lin Z; Wang S; Wang C; Shen W; Lin Y; Shu D; Zhu Z; Kotoi O; Kerwin L; Han Q; Chumakova L; Teijaro J; Royal M; Brunswick M; Allen R; Ji H; Lu H; Xu X
    Med; 2024 Jan; 5(1):42-61.e23. PubMed ID: 38181791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.
    Dampalla CS; Zheng J; Perera KD; Wong LR; Meyerholz DK; Nguyen HN; Kashipathy MM; Battaile KP; Lovell S; Kim Y; Perlman S; Groutas WC; Chang KO
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34210738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An orally available M
    Quan BX; Shuai H; Xia AJ; Hou Y; Zeng R; Liu XL; Lin GF; Qiao JX; Li WP; Wang FL; Wang K; Zhou RJ; Yuen TT; Chen MX; Yoon C; Wu M; Zhang SY; Huang C; Wang YF; Yang W; Tian C; Li WM; Wei YQ; Yuen KY; Chan JF; Lei J; Chu H; Yang S
    Nat Microbiol; 2022 May; 7(5):716-725. PubMed ID: 35477751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment.
    Li P; Kim Y; Dampalla CS; Nhat Nguyen H; Meyerholz DK; Johnson DK; Lovell S; Groutas WC; Perlman S; Chang K-O
    mBio; 2024 Feb; 15(2):e0287823. PubMed ID: 38126789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity.
    Hamdy R; Fayed B; Mostafa A; Shama NMA; Mahmoud SH; Mehta CH; Nayak Y; M Soliman SS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development.
    Zhang Z; Zhou L; Liu Q; Zheng Y; Tan X; Huang Z; Guo M; Wang X; Chen X; Liang S; Li W; Song K; Yan K; Li J; Li Q; Zhang Y; Yang S; Cai Z; Dai M; Xian Q; Shi ZL; Xu K; Lan K; Chen Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2353302. PubMed ID: 38753462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
    Tatham L; Kipar A; Sharp J; Kijak E; Herriott J; Neary M; Box H; Gallardo Toledo E; Valentijn A; Cox H; Pertinez H; Curley P; Arshad U; Rajoli RKR; Rannard S; Stewart JP; Owen A
    Microbiol Spectr; 2024 Aug; 12(8):e0391623. PubMed ID: 39012120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
    Zhu Y; Hu Y; Liu N; Chong H; He Y
    Antiviral Res; 2022 Dec; 208():105445. PubMed ID: 36265805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
    Ghosh A; Chakraborty M; Chandra A; Alam MP
    J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease.
    Alugubelli YR; Xiao J; Khatua K; Kumar S; Sun L; Ma Y; Ma XR; Vulupala VR; Atla S; Blankenship LR; Coleman D; Xie X; Neuman BW; Liu WR; Xu S
    J Med Chem; 2024 Apr; 67(8):6495-6507. PubMed ID: 38608245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological Profiling.
    Alvarez N; Adam GC; Howe JA; Sharma V; Zimmerman MD; Dolgov E; Rasheed R; Nizar F; Sahay K; Nelson AM; Park S; Zhou X; Burlein C; Fay JF; Iwamoto DV; Bahnck-Teets CM; Getty KL; Lin Goh S; Salhab I; Smith K; Boyce CW; Cabalu TD; Murgolo N; Fox NG; Mayhood TW; Shurtleff VW; Layton ME; Parish CA; McCauley JA; Olsen DB; Perlin DS
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses.
    Martinez DR; Moreira FR; Catanzaro NJ; Diefenbacher MV; Zweigart MR; Gully KL; De la Cruz G; Brown AJ; Adams LE; Yount B; Baric TJ; Mallory ML; Conrad H; May SR; Dong S; Scobey DT; Nguyen C; Montgomery SA; Perry JK; Babusis D; Barrett KT; Nguyen AH; Nguyen AQ; Kalla R; Bannister R; Feng JY; Cihlar T; Baric RS; Mackman RL; Bilello JP; Schäfer A; Sheahan TP
    Sci Transl Med; 2024 May; 16(748):eadj4504. PubMed ID: 38776389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
    Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
    J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of highly potent SARS-CoV-2 M
    Chen W; Feng B; Han S; Wang P; Chen W; Zang Y; Li J; Hu Y
    Bioorg Med Chem Lett; 2022 Feb; 58():128526. PubMed ID: 34998903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of meisoindigo derivatives as noncovalent and orally available M
    Gao Q; Liu S; Zhou Y; Fan J; Ke S; Zhou Y; Fan K; Wang Y; Zhou Y; Xia Z; Deng X
    Eur J Med Chem; 2024 Jul; 273():116498. PubMed ID: 38762916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
    Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
    ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.